Cardiovascular PGx.
Know your gene-drug profile. A gene panel for blood thinners, statins, blood pressure and heart-rhythm medications — including warfarin, clopidogrel and the statin family. One saliva sample, run in our CLIA-certified lab, with results your prescriber can refer back to.
- One sample, no blood draw
- Results in 3–7 business days
- Share with any prescriber
Panel
12 genes
Sample
Saliva or cheek swab
Results
3–7 business days
Price
From $289
What we test
Blood thinners, statins, blood pressure and heart rhythm.
See how your genes may affect your response to certain medications. Review your results with your prescriber.
Warfarin — VKORC1, CYP2C9, CYP4F2
The genes behind warfarin dosing: starting dose, bleeding risk and how long you stay therapeutic.
Clopidogrel, prasugrel, ticagrelor — CYP2C19, CYP3A4
Clopidogrel is a pro-drug; poor metabolizers may get little protection. Metabolizer status matters most after a stent.
Statins — SLCO1B1, CYP2C9, ABCG2, CYP3A4
Simvastatin, atorvastatin, rosuvastatin and the rest of the family — SLCO1B1 variants raise the risk of statin muscle pain.
Beta blockers & antiarrhythmics — CYP2D6, ADRA2A
Carvedilol, metoprolol, propranolol, nebivolol, flecainide and propafenone — metabolism changes both effect and side effects.
Inherited thrombosis risk — FII, FV, MTHFR
Inherited clotting variants that inform anticoagulation decisions in you and your relatives.
Who this is for
The same dose can cause bleeding, clotting or side effects in one person and do too little in another.
Blood thinners
Taking or about to start warfarin, clopidogrel or another anticoagulant or antiplatelet.
Statin side effects
Muscle aches or other side effects from a statin may be a metabolism question, not a dose question.
Blood pressure med changes
A medication that needed several dose changes may behave differently at your genes.
Stent or heart procedure
Antiplatelet choice after a stent is one of the most pharmacogenetics-sensitive decisions in cardiology.
Is this test right for you?
You take or are about to start warfarin, clopidogrel or another blood thinner.
A statin gave you muscle aches or other side effects.
Your blood pressure medication needed several dose changes.
You had a stent placed or are planning a heart procedure.
You or close relatives have had blood clots.
Your cardiologist suggested genetic testing.
Answering yes to even one of these is a good reason to test before the next prescription change.
Before you order
Total price
From $289
One-time price, shown in full at checkout before you pay. No separate fee for the kit, return shipping or the healthcare provider order.
What's included
Kit to report
A saliva or cheek-swab kit with instructions, a prepaid return label, the healthcare provider order, genetic testing in our lab and a gene-drug report in your secure portal.
Who orders the test
A licensed healthcare provider
A licensed healthcare provider in our network reviews your request and places the order during checkout, at no extra cost. No referral needed.
Who reviews the results
A board-certified geneticist
Every report is reviewed and signed in our lab by a board-certified molecular geneticist before it is released.
The science
What the evidence says about getting tested.
Cardiovascular drugs are among the most pharmacogenetics-sensitive medications in medicine. Warfarin dosing, clopidogrel activation and statin tolerance all depend on gene variants that clinical guidelines (CPIC, FDA labeling) already recognize. Knowing your metabolizer status before a prescription is written turns guesswork into data.
≈30%
of patients get less antiplatelet protection from standard-dose clopidogrel because of CYP2C19 loss-of-function variants.
Source: CPIC clopidogrel guideline
About 1 in 6
people of European ancestry carry a reduced-function CYP2C19 allele — higher still in East Asian populations.
Source: CPIC clopidogrel guideline
4.5×
higher risk of statin-related muscle symptoms for people carrying two SLCO1B1 reduced-function copies.
Source: SEARCH trial, NEJM 2008
40–60%
of the variability in warfarin dose requirements is explained by VKORC1 and CYP2C9 genetics alone.
Source: Warfarin pharmacogenetics literature
How often should you test?
Test once — your genotype doesn't change. The highest-value moments are before warfarin or clopidogrel is started, immediately after a stent or heart procedure when antiplatelet choice is being made, and after statin muscle symptoms so a switch or dose change is based on evidence rather than trial and error.
References
- Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clinical Pharmacology & Therapeutics. 2013;94(3):317–323.
- Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing: 2017 update. Clinical Pharmacology & Therapeutics. 2017;102(2):197–207.
- Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. New England Journal of Medicine. 2008;359(8):789–799.
- International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. New England Journal of Medicine. 2009;360(8):753–764.
Population data
How common is each metabolizer type?
Published population frequencies for the cytochrome P450 enzymes read on this panel. Your report places you in one of these groups for each enzyme.
| Cytochrome | Poor metabolizer | Intermediate metabolizer | Normal metabolizer | Rapid or ultra-rapid metabolizer |
|---|---|---|---|---|
| CYP2D6 | 4–7% | 9–35% | 50–90% | 2–3% |
| CYP2C9 | 3% | 30% | 68% | N/A |
| CYP2C19 | 2–20% | 24–36% | 14–44% | 30% |
Population frequencies compiled from CPIC guidelines and FDA pharmacogenomic biomarker tables; frequencies vary by ancestry.
Clopidogrel — when guidelines say test
ACCF/AHA acute-coronary-syndrome guidance considers CYP2C19 testing case by case, especially after a recurrent event while on clopidogrel. CPIC recommends an alternative antiplatelet when at least one decreased-function CYP2C19 allele is present, and closer bleeding monitoring for increased metabolizers.
Warfarin — genotype-guided dosing
CPIC publishes a dosing algorithm that combines VKORC1 and CYP2C9 genotypes with clinical factors to estimate the safest starting dose, because warfarin's narrow therapeutic window makes trial-and-error dosing risky.
Statins — the SLCO1B1 check
With at least one reduced-function SLCO1B1 allele, CPIC recommends a reduced simvastatin dose or an alternative statin, since higher drug exposure raises the risk of muscle toxicity.
Voriconazole — CPIC dosing guidance
CPIC recommends an alternative agent for CYP2C19 rapid and ultra-rapid metabolizers, because therapeutic levels may never be reached, and for poor metabolizers, because levels climb into the toxic range. The difference matters most in time-critical infections such as invasive aspergillosis.
How widespread is gene-affected prescribing?
More than 250 medicines list pharmacogenomic information in their FDA-approved labeling, and one study estimated 63% of adults and 29% of children with pharmacy coverage had been prescribed at least one gene-affected medication (Liu et al., 2021).
Questions people actually ask
Bring data to your next cardiology visit.
One sample, one flat price, a report your prescribers can refer back to.